Jefferies Group set a $13.00 price objective on Xenon Pharmaceuticals Inc. (NASDAQ:XENE) in a research report released on Monday morning. The firm currently has a buy rating on the biopharmaceutical company’s stock.

XENE has been the topic of a number of other research reports. Stifel Nicolaus initiated coverage on Xenon Pharmaceuticals in a report on Friday, October 21st. They set a buy rating and a $18.00 price target on the stock. Zacks Investment Research raised Xenon Pharmaceuticals from a sell rating to a hold rating in a report on Thursday, October 6th. Canaccord Genuity reaffirmed a buy rating and set a $16.00 price target on shares of Xenon Pharmaceuticals in a report on Friday, August 5th. Finally, Guggenheim initiated coverage on Xenon Pharmaceuticals in a report on Monday, September 26th. They set a buy rating and a $20.00 price target on the stock. Five analysts have rated the stock with a buy rating, Xenon Pharmaceuticals currently has an average rating of Buy and a consensus target price of $15.15.

Shares of Xenon Pharmaceuticals (NASDAQ:XENE) opened at 7.80 on Monday. The firm’s market cap is $139.57 million. Xenon Pharmaceuticals has a 12-month low of $5.65 and a 12-month high of $9.48. The stock’s 50 day moving average price is $8.08 and its 200 day moving average price is $7.56.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its quarterly earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($0.51) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.43) by $0.08. Xenon Pharmaceuticals had a negative net margin of 449.72% and a negative return on equity of 34.72%. On average, equities research analysts predict that Xenon Pharmaceuticals will post ($1.57) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was reported by Financial Market News and is the sole property of of Financial Market News. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The original version of this report can be read at http://www.financial-market-news.com/jefferies-group-analysts-give-xenon-pharmaceuticals-inc-xene-a-13-00-price-target/1212136/.

A number of large investors have recently made changes to their positions in XENE. BVF Inc. IL boosted its stake in shares of Xenon Pharmaceuticals by 75.1% in the third quarter. BVF Inc. IL now owns 3,108,905 shares of the biopharmaceutical company’s stock valued at $25,182,000 after buying an additional 1,333,333 shares during the last quarter. Sphera Funds Management LTD. bought a new position in Xenon Pharmaceuticals during the third quarter valued at about $1,847,000. Perceptive Advisors LLC boosted its position in Xenon Pharmaceuticals by 110.3% in the second quarter. Perceptive Advisors LLC now owns 432,800 shares of the biopharmaceutical company’s stock valued at $2,553,000 after buying an additional 227,000 shares in the last quarter. Monashee Investment Management LLC bought a new position in Xenon Pharmaceuticals during the third quarter valued at about $203,000. Finally, K2 Principal Fund L.P. bought a new position in Xenon Pharmaceuticals during the third quarter valued at about $122,000. 55.44% of the stock is currently owned by hedge funds and other institutional investors.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc (Xenon) is a biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications. The Company’s platform, Extreme Genetics, enables the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels (channelopathies).

5 Day Chart for NASDAQ:XENE

Receive News & Ratings for Xenon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.